Specialty Pharma Journal Specialty, Precision & Technology
RARITAN, N.J., Nov. 9, 2015 /PRNewswire/ — Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing Phase 1 and expected to enter Phase 2 studies next year, from Hanmi Pharmaceutical …
Tag Archives: Hanmi Pharmaceutical
November, 2015
-
5 November
Sanofi Enters Diabetes License Deal with Hanmi Pharmaceutical
PARIS and SEOUL, South Korea, Nov. 5, 2015 /PRNewswire-USNewswire/ — Sanofi and Hanmi Pharmaceutical Co., Ltd. announced today a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments. Under the terms of the agreement, Hanmi will receive an upfront payment of €400 million and is eligible for up …
March, 2015
-
19 March
Lilly Partners with Hanmi for Autoimmune Disorder Drug
Eli Lilly and Company is shelling out up to $690 million for access to Hanmi Pharmaceutical’s Phase I compound HM71224, in development for autoimmune diseases. The companies announced today that they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi’s oral Bruton’s tyrosine …